Pharmaceutical Commerce - November/December 2016 - 22


Supply Chain/Logistics
A new approach to pharma supply-chain collaboration
Team-Up seeks to bring manufacturers and logistics providers together
By Alan Kennedy, Executive Director, Team-Up

Market expectations of service
and quality are continuously advancing.
The health product consumer of
today seeks and expects more service,
more safety, more value and more
customization. For this to happen
requires enormous, and continuous,
efficiency improvements on the part of
the manufacturer.
However, productivity dividends are, like many things,
subject to the law of diminishing returns. Supply network
optimization offers a clear route to meeting the escalating
requirements of the market while securing the longterm profitability and market respect of the participating
organizations. Among the industr y's more savvy
organizations, the efficiency battleground is moving from the
factory to the supply chain with huge potential for efficiency
gains, cost savings and competitive advantage.
Grass roots
Research by Accenture has indicated that, by implementing
global strategies to optimize freight-related spend, shippers
can lower transportation costs by up to 25%. Similar levels
of savings have been recorded in other studies of pharma
logistics rationalization. The bottom line is that major
pharma shippers, especially those with multinational
manufacturing and marketing interests, have it within their
grasp to extract orders-of-magnitude improvements in value
if they are prepared to support collaborative delivery models
that go right down to the industry's grass roots.
The new Team-Up initiative operates as a shipper-driven,
single-focus 'best practice' group specifically promoting
strategic partnering between all players in the pharmalogistics process. With this in mind, the Team-Up program
came out of exploratory discussions at the LogiPharma
2016 Conference in Montreux followed by a roundtable
consultation with key stakeholders. The idea behind the
consultation process was to bring a senior representative from

each of the main pharma-logistics stakeholders around a table
to explore the potential for genuine end-to-end collaboration.
The need for reform
In the case of pharmaceutical manufacturing, the processes
concerned are generally under continuous efficiency review
and, as a result, most of the "low-hanging" productivity
gains are quickly picked up. In contrast, pharma-logistics
operations tend to be relatively comatose, often escaping
root and branch analysis by pharma producers on account of
their 'non-core business' status, and the anticipated cost and
disruption of change.
However, it is becoming increasingly difficult to reconcile
the growing demands for reduced costs with those for
improved performance. Logistics companies are having to
negotiate an ever more intricate labyrinth of regulations,
performance standards and shipping routes while maintaining
the profitability necessary for innovation, business
development and shareholder return.
These logistical challenges are particularly acute
in developing regions where there may be additional risks
associated with infrastructure limitations, tax, duty and
regulatory complications, poor market data, ramp and handling
inefficiencies, language barriers, and a lack of trained manpower.
Goals
Team-Up is seeking to emulate the radical supply-chain
re-engineering that is a recurring feature of many other
logistics-intensive industries such as automotive, retail,
aerospace and construction.
A preliminary portfolio of Team-Up goals includes:
* Realigning the corporate culture of pharma logistics to
better support integrated working.
* S haring collaborative best practice and providing
the industry with practical advice and tools in order to
standardize partnering methodologies and facilitate the
assembly of integrated supply networks.

* P roviding shippers and logistics providers with a
recognized accreditation status for exemplary collaborative
working and to promote these credentials to all sector
stakeholders.
* Strengthening the business case for integrated supply
networks by building an evidence-base from pilot programs
and other evaluations.
Independent
Team-Up operates independently of any existing bodies
and movements, and is not associated with any vested interest
groups or particular segments of the supply chain. This makes
it relevant to the entire pharma-logistics sector, including all
modes of transport-air, ground and ocean. The Team-Up
approach is of universal validity and has no geographical
barriers-local, national or international. Furthermore, the
Team-Up approach has been designed to foster the collaborative
working practices that are implicit in partnership-dependent
programs, such as IATA's CEIV program, the Pharma.Aero
group and other industry collectives.
Get involved
Planning sessions are being held in late 2016 with a formal
kickoff slated for early 2017. We invite all interested parties to
contact the Team-Up organization and play an active role in
its development. Contact us via www.team-up.global.
About the Author
Alan Kennedy is a collaboration consultant and executive
director of Team-Up. A pioneer of integrated supply chain
working, Alan first got involved in the practical implementation
of collaborative working methods in supply chains while
working with the Electrolux Group in the 1980s. More recently,
he has been involved in bringing best-collaborative practices
to the pharma-logistics sector. He has presented at many
conferences and published numerous papers on the subject
of supply chain collaboration and integration. He can be
reached at a.kennedy@team-up.global.

Clinical Operations
ATCC broadens its resources for cell lines to research cancer
New resources for precision medicine
A flurry of announcements from
American Type Cell Culture (ATCC;
Manassas, VA) signal a major commitment
to new resources and capabilities in
providing cells and cancer "models" (a
term that refers to cell lines with particular
genomic characteristics) to academic
and commercial researchers. ATCC, a
nonprofit, has been for years a repository
of human cells, bacteria, yeasts and viruses;
it also develops standardized materials and
protocols for working with these biological
materials in drug development and research.
In July, the National Cancer Institute
announced the formation of the Human
Cancer Models Initiative, which brought
together NCI with Cancer Research UK,
the Wellcome Trust Sanger Institute and the
foundation Hubrecht Organoid Technology.

Together, these organizations will "generate
new models of cancer that more accurately
represent human tumors," according to an
NCI statement. Of particular interest is
the development of "organoids," which are
three-dimensional organ-buds, grown in
vitro, that show realistic micro-anatomy.
That technology itself is only a few years
old. NCI contracts with a company called
Leidos Biomed to manage a biorepository in
Frederick, MD, said to be one of the world's
largest. Leidos, in turn, is subcontracting
the management of the facility to ATCC.
Under a separate contract, NCI has
chosen ATCC to manage the intake,
authentication, production marketing and
distribution of the cancer models. These
models "will be generated using tumor
tissue from patients with a variety of cancer

22 Visit our website at www.PharmaceuticalCommerce.com November | December 2016

types, including rare and pediatric cancers,
and will include a complete genetic analysis
and anonymized clinical information about
the patients and their tumors, including
their response to treatment," according to
ATCC.
And in May, ATCC renewed a multiyear
contract with the National Institute of
Allergy and Infectious Diseases to manage
a repository of those biologic samples and
compounds. This contract work has been
ongoing since 2003.
F i n a l l y, AT C C a n n o u n c e d a
collaboration with BioAgilytix, a leading
bioanalytical testing laboratory specializing
in large molecule bioanalysis. Together, the
organizations will develop new and custom
cell lines, with ATCC providing reagents
and cells complementing the bioassays

BioAgilytix develops. The technology is
said to "establish the potency and stability
of therapeutic products and help establish
their safety and efficacy profiles."
On its own, ATCC maintains a 126,000sq. ft. facility in Manassas that contains 200
freezers, including vapor-phase nitrogen
freezers, mechanical freezers and cold
rooms. Some 3,400 cell lines are maintained
there.


http://www.Pharma.Aero http://www.team-up.global http://pharmaceuticalcommerce.com/

Table of Contents for the Digital Edition of Pharmaceutical Commerce - November/December 2016

Table of Contents
Pharmaceutical Commerce - November/December 2016 - Cover1
Pharmaceutical Commerce - November/December 2016 - Cover2
Pharmaceutical Commerce - November/December 2016 - Table of Contents
Pharmaceutical Commerce - November/December 2016 - 4
Pharmaceutical Commerce - November/December 2016 - 5
Pharmaceutical Commerce - November/December 2016 - 6
Pharmaceutical Commerce - November/December 2016 - 7
Pharmaceutical Commerce - November/December 2016 - 8
Pharmaceutical Commerce - November/December 2016 - 9
Pharmaceutical Commerce - November/December 2016 - 10
Pharmaceutical Commerce - November/December 2016 - 11
Pharmaceutical Commerce - November/December 2016 - 12
Pharmaceutical Commerce - November/December 2016 - 13
Pharmaceutical Commerce - November/December 2016 - 14
Pharmaceutical Commerce - November/December 2016 - 15
Pharmaceutical Commerce - November/December 2016 - 16
Pharmaceutical Commerce - November/December 2016 - 17
Pharmaceutical Commerce - November/December 2016 - 18
Pharmaceutical Commerce - November/December 2016 - 19
Pharmaceutical Commerce - November/December 2016 - 20
Pharmaceutical Commerce - November/December 2016 - 21
Pharmaceutical Commerce - November/December 2016 - 22
Pharmaceutical Commerce - November/December 2016 - 23
Pharmaceutical Commerce - November/December 2016 - 24
Pharmaceutical Commerce - November/December 2016 - 25
Pharmaceutical Commerce - November/December 2016 - 26
Pharmaceutical Commerce - November/December 2016 - 27
Pharmaceutical Commerce - November/December 2016 - Cover4
http://www.nxtbook.com/nxtbooks/pharmcomm/201911
http://www.nxtbook.com/nxtbooks/pharmcomm/201909
http://www.nxtbook.com/nxtbooks/pharmcomm/201906
http://www.nxtbook.com/nxtbooks/pharmcomm/201903
http://www.nxtbook.com/nxtbooks/pharmcomm/201811
http://www.nxtbook.com/nxtbooks/pharmcomm/201809
http://www.nxtbook.com/nxtbooks/pharmcomm/201806
http://www.nxtbook.com/nxtbooks/pharmcomm/20180304
http://www.nxtbook.com/nxtbooks/pharmcomm/20171112
http://www.nxtbook.com/nxtbooks/pharmcomm/20170910
http://www.nxtbook.com/nxtbooks/pharmcomm/20170708
http://www.nxtbook.com/nxtbooks/pharmcomm/20170506
http://www.nxtbook.com/nxtbooks/pharmcomm/20170304
http://www.nxtbook.com/nxtbooks/pharmcomm/20170102
http://www.nxtbook.com/nxtbooks/pharmcomm/20161112
http://www.nxtbook.com/nxtbooks/pharmcomm/20160910
http://www.nxtbook.com/nxtbooks/pharmcomm/20160708
http://www.nxtbook.com/nxtbooks/pharmcomm/20160506
http://www.nxtbook.com/nxtbooks/pharmcomm/20160304
http://www.nxtbook.com/nxtbooks/pharmcomm/20160102
http://www.nxtbook.com/nxtbooks/pharmcomm/20151112
http://www.nxtbook.com/nxtbooks/pharmcomm/20150910
http://www.nxtbook.com/nxtbooks/pharmcomm/20150708
http://www.nxtbook.com/nxtbooks/pharmcomm/20150506
http://www.nxtbook.com/nxtbooks/pharmcomm/20150304
http://www.nxtbook.com/nxtbooks/pharmcomm/20150102
http://www.nxtbook.com/nxtbooks/pharmcomm/20141112
http://www.nxtbook.com/nxtbooks/pharmcomm/coldchaindirectory2014
http://www.nxtbook.com/nxtbooks/pharmcomm/20140910
http://www.nxtbook.com/nxtbooks/pharmcomm/20140708
http://www.nxtbook.com/nxtbooks/pharmcomm/20140506
http://www.nxtbook.com/nxtbooks/pharmcomm/20140304
http://www.nxtbook.com/nxtbooks/pharmcomm/20140102
http://www.nxtbook.com/nxtbooks/pharmcomm/dataservicedirectory
http://www.nxtbook.com/nxtbooks/pharmcomm/20131112
http://www.nxtbook.com/nxtbooks/pharmcomm/20130910_hubreport
http://www.nxtbook.com/nxtbooks/pharmcomm/20130910
http://www.nxtbook.com/nxtbooks/pharmcomm/20130708
http://www.nxtbook.com/nxtbooks/pharmcomm/20130506
http://www.nxtbook.com/nxtbooks/pharmcomm/coldchain2013
http://www.nxtbook.com/nxtbooks/pharmcomm/20130304
http://www.nxtbook.com/nxtbooks/pharmcomm/20130102
http://www.nxtbook.com/nxtbooks/pharmcomm/20121112
http://www.nxtbook.com/nxtbooks/pharmcomm/20120910
http://www.nxtbook.com/nxtbooks/pharmcomm/20120708
http://www.nxtbook.com/nxtbooks/pharmcomm/20120506
http://www.nxtbook.com/nxtbooks/pharmcomm/20120506_coldchain
http://www.nxtbook.com/nxtbooks/pharmcomm/20120304
http://www.nxtbook.com/nxtbooks/pharmcomm/20120102
http://www.nxtbook.com/nxtbooks/pharmcomm/20111112
http://www.nxtbook.com/nxtbooks/pharmcomm/20110910
http://www.nxtbook.com/nxtbooks/pharmcomm/20110708
http://www.nxtbook.com/nxtbooks/pharmcomm/20110506
http://www.nxtbook.com/nxtbooks/pharmcomm/20110304
http://www.nxtbook.com/nxtbooks/pharmcomm/20110102
http://www.nxtbook.com/nxtbooks/pharmcomm/20101112
http://www.nxtbook.com/nxtbooks/pharmcomm/20100910
http://www.nxtbook.com/nxtbooks/pharmcomm/20100708
http://www.nxtbook.com/nxtbooks/pharmcomm/20100506
http://www.nxtbook.com/nxtbooks/pharmcomm/201004
http://www.nxtbook.com/nxtbooks/pharmcomm/201003
http://www.nxtbook.com/nxtbooks/pharmcomm/20100102
http://www.nxtbook.com/nxtbooks/pharmcomm/20091112
http://www.nxtbookMEDIA.com